Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER-155 in HSCT patients
NCT04995653Phase 1Completed
- Sponsor
- Seres Therapeutics
- Start
- Nov 2021
- Primary completion
- Jul 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SER-155 in bacterial bloodstream infection (BSI) and graft-versus-host disease (GVHD) (3 cohorts), sponsored by Seres Therapeutics. Primary endpoints: Safety and tolerability at Day 100 and Engraftment of SER-155 at Day 100. Started Nov 2021; status: completed.
02
Drugs
SER-155
03
Conditions
bacterial bloodstream infection (BSI)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04995653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995653.